{"id":22401,"date":"2023-03-09T09:52:15","date_gmt":"2023-03-09T17:52:15","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=22401"},"modified":"2024-01-29T11:40:40","modified_gmt":"2024-01-29T11:40:40","slug":"polivy-polatuzumab-vedotoin-piiq","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/","title":{"rendered":"Polivy (Polatuzumab vedoto\u00edna-piiq)"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">La forma m\u00e1s frecuente de linfoma no Hodgkin (LNH), tanto en Estados Unidos como a nivel mundial, se conoce como linfoma difuso de c\u00e9lulas B grandes (LDCBG). Este tipo de c\u00e1ncer afecta a los linfocitos B, los gl\u00f3bulos blancos del cuerpo. Normalmente, estos linfocitos ayudan a combatir infecciones. Sin embargo, en el caso del linfoma difuso de c\u00e9lulas B grandes (LDCBG), el linfocito crece m\u00e1s r\u00e1pido y m\u00e1s grande de lo normal, lo que le permite funcionar de forma anormal o no funcionar en absoluto. Estos linfocitos tambi\u00e9n se acumulan en diversas partes del cuerpo, incluidos los ganglios linf\u00e1ticos, debido a su alta tasa de proliferaci\u00f3n.<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-45855f348cb32f58913d03a744378456\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p><span style=\"font-weight: 400;\">En este art\u00edculo, revisaremos Polivy, uno de los medicamentos que se han desarrollado y aprobado para el tratamiento del DLBCL.<\/span><\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#What_Is_Polivy\" >\u00bfQu\u00e9 es Polivy?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#How_Polivy_Works\" >C\u00f3mo funciona Polivy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#Approval_and_Effectiveness\" >Aprobaci\u00f3n y eficacia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#How_Is_Polivy_Administered\" >\u00bfC\u00f3mo se administra Polivy?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#Dosage\" >Dosificaci\u00f3n<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#Side_Effects\" >Efectos secundarios<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#Mild_Side_Effects\" >Efectos secundarios leves<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#Possible_Adverse_Side_Effects\" >Posibles efectos secundarios adversos<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#Cost\" >Costo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Polivy\"><\/span>\u00bfQu\u00e9 es Polivy?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Polivy (nombre gen\u00e9rico: polatuzumab vedotoin-piiq) es un f\u00e1rmaco creado y aprobado para el tratamiento del linfoma difuso de c\u00e9lulas B grandes en pacientes adultos. El LDCBG afecta los gl\u00f3bulos blancos del organismo y reduce la capacidad del sistema inmunitario para combatir infecciones.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">El Polivy solo puede usarse para tratar el LDCBG despu\u00e9s de que otros dos medicamentos y opciones terap\u00e9uticas no hayan mejorado la afecci\u00f3n. Esto significa que solo se puede tratar el LDCBG con Polivy si la afecci\u00f3n ha reca\u00eddo o es resistente a otras opciones de tratamiento. Otros dos tratamientos contra el c\u00e1ncer, conocidos como rituximab y bendamustina, se utilizan en combinaci\u00f3n con Polivy para tratar el LDCBG.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Polivy_Works\"><\/span>C\u00f3mo funciona Polivy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El principio activo de Polivy se conoce como polatuzumab vedotin-piiq. Este agente es un conjugado anticuerpo-f\u00e1rmaco que se une al anticuerpo conocido como prote\u00edna CD76b. La uni\u00f3n de Polivy a la prote\u00edna CD76b facilita que el principio activo ataque a los linfocitos B del organismo, incluyendo las c\u00e9lulas malignas.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">El medicamento localiza las c\u00e9lulas B deseadas y libera su principio activo, destruyendo los gl\u00f3bulos blancos B. Tambi\u00e9n ataca y destruye los linfocitos B cancerosos. Tras la dosis inicial, el medicamento empieza a surtir efecto. Sin embargo, es posible que el m\u00e9dico deba realizar algunas pruebas para garantizar la eficacia del medicamento.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Approval_and_Effectiveness\"><\/span>Aprobaci\u00f3n y eficacia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">En 2019, la Administraci\u00f3n de Alimentos y Medicamentos (FDA) autoriz\u00f3 el Polivy para el tratamiento del linfoma difuso de c\u00e9lulas B grandes (LDCBG). Sin embargo, el medicamento recibi\u00f3 <\/span><a href=\"https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval\"><span style=\"font-weight: 400;\">aprobaci\u00f3n acelerada<\/span><\/a><span style=\"font-weight: 400;\"> de la FDA, lo que significa que el medicamento fue aprobado y puesto a disposici\u00f3n del p\u00fablico para su uso antes de la conclusi\u00f3n de sus ensayos cl\u00ednicos.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Este tipo de aprobaci\u00f3n suele otorgarse a medicamentos que se utilizan para tratar enfermedades raras, como el linfoma difuso de c\u00e9lulas B (LDCBG), debido a que estas enfermedades no ofrecen muchas opciones de tratamiento. La decisi\u00f3n de otorgar o no la aprobaci\u00f3n completa a Polivy se tomar\u00e1 tras la conclusi\u00f3n de los ensayos cl\u00ednicos.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Sin embargo, el <\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121Orig1s003lbl.pdf\"><span style=\"font-weight: 400;\">estudios y ensayos cl\u00ednicos<\/span><\/a><span style=\"font-weight: 400;\"> Los estudios realizados hasta el momento sobre la eficacia del f\u00e1rmaco han sido positivos. Seg\u00fan la Red Nacional Integral del C\u00e1ncer, las directrices de tratamiento para el linfoma difuso de c\u00e9lulas B grandes (LDCBG) incluyen Polivy como opci\u00f3n terap\u00e9utica recomendada.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Is_Polivy_Administered\"><\/span>\u00bfC\u00f3mo se administra Polivy?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El Polivy se administra mediante infusiones intravenosas, que consisten en inyecciones en la vena durante un tiempo. Esto significa que deber\u00e1 estar cerca de profesionales sanitarios en un hospital o centro de infusi\u00f3n para recibir su dosis de Polivy.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">La primera dosis de infusi\u00f3n de Polivy suele durar unos 90 minutos. Las siguientes dosis duran unos 30 minutos cada una. Idealmente, se administra una dosis de Polivy cada 21 d\u00edas. El tratamiento suele consistir en seis ciclos.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage\"><\/span>Dosificaci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient.jpg\" alt=\"Nurse with Polivy patient\" class=\"wp-image-22403\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/nurse-patient-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p><span style=\"font-weight: 400;\">La dosis adecuada de Polivy para tratar el LDCBG depende de muchos factores. Los principales son el peso y los posibles efectos secundarios. Su m\u00e9dico considerar\u00e1 algunos de estos factores para determinar la dosis correcta de Polivy para usted.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">El medicamento generalmente viene en forma de l\u00edquido en un vial mezclado con agua esterilizada.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">El Polivy est\u00e1 disponible en dos concentraciones: 30 mg y 140 mg por vial. La dosis para tratar el LDCBG con Polivy es de 1,8 mg por kg. Por lo tanto, su peso determinar\u00e1 la dosis adecuada. Por ejemplo, una persona que pesa 77 kg necesitar\u00eda un vial de 140 mg para una infusi\u00f3n.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Si no acude a una cita para la infusi\u00f3n, llame al centro de salud donde la recibe y reprograme la cita lo antes posible. Tambi\u00e9n debe informar al m\u00e9dico sobre la cita perdida, ya que esto podr\u00eda afectar su programa de tratamiento.\u00a0<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-cc4c11200818c137b3a7dcd63a7175ba\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago Polivy\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAsistencia financiera\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Side_Effects\"><\/span>Efectos secundarios<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Los efectos secundarios asociados con Polivy suelen variar de leves a graves. Algunos de los efectos secundarios que podr\u00eda experimentar incluyen:&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mild_Side_Effects\"><\/span><b>Efectos secundarios leves<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Mareo<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Fiebre<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Fatiga<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Reacci\u00f3n al\u00e9rgica leve<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Diarrea<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">P\u00e9rdida de peso<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Niveles bajos de potasio, alb\u00famina y calcio en la sangre.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">disminuci\u00f3n del apetito<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Infecciones de las v\u00edas respiratorias superiores como el resfriado com\u00fan&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">V\u00f3mitos<\/span><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Possible_Adverse_Side_Effects\"><\/span><b>Posibles efectos secundarios adversos<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Estas reacciones adversas no son comunes y ocurren raramente. Sin embargo, si experimenta alguna, debe contactar inmediatamente con su centro de salud. Estos efectos secundarios incluyen:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\"><a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/neuropathy-types-causes-symptoms-and-treatment\/\">neuropat\u00eda perif\u00e9rica<\/a>, que es una forma de da\u00f1o nervioso que se caracteriza por hormigueo, entumecimiento, debilidad muscular y espasmos.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">S\u00edndrome de lisis tumoral, que ocurre cuando las c\u00e9lulas cancerosas se descomponen y liberan ciertas sustancias en el torrente sangu\u00edneo.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Infecciones graves como neumon\u00eda, que pueden provocar sepsis.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Reacciones a la infusi\u00f3n que ocurren aproximadamente 24 horas despu\u00e9s de una infusi\u00f3n.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Leucoencefalopat\u00eda multifocal progresiva<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Aumento de los niveles de enzimas hep\u00e1ticas<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Nivel bajo de plaquetas<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Anemia<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Reacci\u00f3n al\u00e9rgica grave<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Niveles bajos de gl\u00f3bulos blancos espec\u00edficos<\/span><\/li>\n<\/ul>\n\n\n\n<p><span style=\"font-weight: 400;\">Tenga en cuenta que la FDA a\u00fan est\u00e1 monitoreando algunos de los efectos secundarios asociados con el uso de Polivy. Tambi\u00e9n puede reportar efectos secundarios que no est\u00e9n listados a trav\u00e9s de&nbsp; <\/span><a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/medwatch\/index.cfm\"><span style=\"font-weight: 400;\">MedWatch<\/span><\/a><span style=\"font-weight: 400;\"> o puede llamar al 1-800-DA-1088.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Costo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El costo de Polivy es de aproximadamente $3,530 por un vial de 30 mg. El precio final que pague depende de muchos factores, como su seguro m\u00e9dico, su ubicaci\u00f3n y la farmacia que utilice.&nbsp;<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>La forma m\u00e1s frecuente de linfoma no Hodgkin (LNH), tanto en Estados Unidos como a nivel mundial, se conoce como linfoma difuso de c\u00e9lulas B grandes (LDCBG). Este tipo de c\u00e1ncer afecta a los linfocitos B, los gl\u00f3bulos blancos del cuerpo.<\/p>","protected":false},"author":16,"featured_media":22402,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[13],"tags":[21],"class_list":["post-22401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","tag-dr-martina-mikail"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Polivy (Polatuzumab Vedotoin-piiq) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Essential information about Polivy (Polatuzumab Vedotoin-piiq). Topics include how the drug works, side effects, dosage and more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Polivy (Polatuzumab Vedotoin-piiq) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Essential information about Polivy (Polatuzumab Vedotoin-piiq). Topics include how the drug works, side effects, dosage and more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-09T17:52:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-29T11:40:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Martina Mikail, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Martina Mikail, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/\"},\"author\":{\"name\":\"Dr. Martina Mikail, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/person\\\/1a08790136f47e0a1978629cdfeca933\"},\"headline\":\"Polivy (Polatuzumab Vedotoin-piiq)\",\"datePublished\":\"2023-03-09T17:52:15+00:00\",\"dateModified\":\"2024-01-29T11:40:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/\"},\"wordCount\":944,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/polivy-patient.jpg\",\"keywords\":[\"Dr. Martina Mikail\"],\"articleSection\":[\"Cancer\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/\",\"name\":\"Polivy (Polatuzumab Vedotoin-piiq) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/polivy-patient.jpg\",\"datePublished\":\"2023-03-09T17:52:15+00:00\",\"dateModified\":\"2024-01-29T11:40:40+00:00\",\"description\":\"Essential information about Polivy (Polatuzumab Vedotoin-piiq). Topics include how the drug works, side effects, dosage and more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/polivy-patient.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/polivy-patient.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Polivy patient with lymphoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cancer\\\/polivy-polatuzumab-vedotoin-piiq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Polivy (Polatuzumab Vedotoin-piiq)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/person\\\/1a08790136f47e0a1978629cdfeca933\",\"name\":\"Dr. Martina Mikail, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80314ccb70a255a42c79b579c4d8558683df0bb73c133efa5c0d8896353e2b79?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80314ccb70a255a42c79b579c4d8558683df0bb73c133efa5c0d8896353e2b79?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80314ccb70a255a42c79b579c4d8558683df0bb73c133efa5c0d8896353e2b79?s=96&d=mm&r=g\",\"caption\":\"Dr. Martina Mikail, PharmD\"},\"description\":\"Dr. Martina Mikail, PharmD was born in Egypt and raised in Pennsylvania and California. She graduated from Marshall B. Ketchum University in May 2022. Dr. Mikail is a recipent of the USPS Leadership Award and the CSHP Leadership Award, and is an active member of CSHP, ASHP, and APhA. The most rewarding part of her job is educating patients and counseling them on medications. In her free time, she likes to cook, spend time with family, and read.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/martina-mikail\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Polivy (Polatuzumab Vedotoin-piiq) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Informaci\u00f3n esencial sobre Polivy (Polatuzumab Vedotoin-piiq). Incluye informaci\u00f3n sobre su acci\u00f3n, efectos secundarios, dosis y m\u00e1s.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/","og_locale":"es_MX","og_type":"article","og_title":"Polivy (Polatuzumab Vedotoin-piiq) - AmeriPharma\u00ae Specialty Care","og_description":"Essential information about Polivy (Polatuzumab Vedotoin-piiq). Topics include how the drug works, side effects, dosage and more.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/polivy-polatuzumab-vedotoin-piiq\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2023-03-09T17:52:15+00:00","article_modified_time":"2024-01-29T11:40:40+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg","type":"image\/jpeg"}],"author":"Dr. Martina Mikail, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Martina Mikail, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/"},"author":{"name":"Dr. Martina Mikail, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/person\/1a08790136f47e0a1978629cdfeca933"},"headline":"Polivy (Polatuzumab Vedotoin-piiq)","datePublished":"2023-03-09T17:52:15+00:00","dateModified":"2024-01-29T11:40:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/"},"wordCount":944,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg","keywords":["Dr. Martina Mikail"],"articleSection":["Cancer"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/","url":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/","name":"Polivy (Polatuzumab Vedotoin-piiq) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg","datePublished":"2023-03-09T17:52:15+00:00","dateModified":"2024-01-29T11:40:40+00:00","description":"Informaci\u00f3n esencial sobre Polivy (Polatuzumab Vedotoin-piiq). Incluye informaci\u00f3n sobre su acci\u00f3n, efectos secundarios, dosis y m\u00e1s.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg","width":1280,"height":853,"caption":"Polivy patient with lymphoma"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/cancer\/polivy-polatuzumab-vedotoin-piiq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/vi\/"},{"@type":"ListItem","position":2,"name":"Polivy (Polatuzumab Vedotoin-piiq)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#website","url":"https:\/\/ameripharmaspecialty.com\/vi\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/vi\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/person\/1a08790136f47e0a1978629cdfeca933","name":"Dra. Martina Mikail, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/80314ccb70a255a42c79b579c4d8558683df0bb73c133efa5c0d8896353e2b79?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80314ccb70a255a42c79b579c4d8558683df0bb73c133efa5c0d8896353e2b79?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80314ccb70a255a42c79b579c4d8558683df0bb73c133efa5c0d8896353e2b79?s=96&d=mm&r=g","caption":"Dr. Martina Mikail, PharmD"},"description":"La Dra. Martina Mikail, doctora en farmacia, naci\u00f3 en Egipto y creci\u00f3 en Pensilvania y California. Se gradu\u00f3 de la Universidad Marshall B. Ketchum en mayo de 2022. La Dra. Mikail ha recibido los Premios de Liderazgo del Servicio Postal de los Estados Unidos (USPS) y del CSHP, y es miembro activo de CSHP, ASHP y APhA. Lo m\u00e1s gratificante de su trabajo es educar a los pacientes y asesorarlos sobre sus medicamentos. En su tiempo libre, le gusta cocinar, pasar tiempo con su familia y leer.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/martina-mikail\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Martina Mikail, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/martina-mikail\/"},"uagb_comment_info":0,"uagb_excerpt":"The most prevalent form of non-Hodgkin\u2019s lymphoma (NHL) in both the United States and worldwide is known as diffuse large B-cell lymphoma (DLBCL). Diffuse large B-Cell lymphoma (DLBCL) is a type of cancer that affects the white blood cells in the body known as B-Cell lymphocytes.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/polivy-patient.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Martina Mikail, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/martina-mikail\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/cancer\/\" rel=\"category tag\">Cancer<\/a>","rttpg_excerpt":"The most prevalent form of non-Hodgkin\u2019s lymphoma (NHL) in both the United States and worldwide is known as diffuse large B-cell lymphoma (DLBCL). Diffuse large B-Cell lymphoma (DLBCL) is a type of cancer that affects the white blood cells in the body known as B-Cell lymphocytes.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=22401"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22401\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/22402"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=22401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=22401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=22401"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}